Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia. According...
ThisCART19A by Suzhou Fundamenta Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell...
ThisCART19A by Suzhou Fundamenta Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to...
ThisCART19A by Suzhou Fundamenta Therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....
ThisCART19A by Suzhou Fundamenta Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL)....